Skip to main content
Print Save

Tecentriq Side Effects

Generic name: atezolizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Oct 18, 2021.

Note: This document contains side effect information about atezolizumab. Some dosage forms listed on this page may not apply to the brand name Tecentriq.

Summary

Common side effects of Tecentriq include: herpes simplex encephalitis, infection, mycobacterium infection, retroperitoneal hemorrhage, sepsis, severe infection, urinary tract infection, colitis, diarrhea, and increased thyroid stimulating hormone level. Continue reading for a comprehensive list of adverse effects.

Applies to atezolizumab: parenteral injection.

Side effects include:

Single-agent atezolizumab (the active ingredient contained in Tecentriq) (≥20%): Fatigue or asthenia, nausea, cough, dyspnea, decreased appetite.

In combination with other antineoplastic agents in patients with NSCLC or SCLC (≥20%): Fatigue or asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite.

In combination with albumin-bound paclitaxel in patients with triple-negative breast cancer (≥20%): Alopecia, peripheral neuropathy, fatigue, nausea, diarrhea, constipation, cough, headache, vomiting, decreased appetite; laboratory abnormalities occurring in ≥50% of patients include decreased concentrations of hemoglobin, leukocytes, neutrophils, and lymphocytes.

In combination with bevacizumab in patients with HCC (≥20%): Hypertension, fatigue, proteinuria.

In combination with cobimetinib and vemurafenib in patients with melanoma (≥20%): Rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, photosensitivity.

For Healthcare Professionals

Applies to atezolizumab: intravenous solution.

Cardiovascular

Common (1% to 10%): Venous thromboembolism[Ref]

Dermatologic

Very common (10% or more): Rash (15%), pruritus (13%)[Ref]

Endocrine

Frequency not reported: Immune-related thyroid disorders (e.g., hyperthyroidism, hypothyroidism)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (25%), constipation (21%), diarrhea (18%), abdominal pain (17%), vomiting (17%)

Common (1% to 10%): Dehydration, intestinal obstruction[Ref]

General

The most common adverse reactions (greater than 20%) were fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation. The most common Grade 3 to 4 adverse reactions (greater than 2%) were urinary tract infection, anemia, fatigue, dehydration, intestinal obstruction, urinary obstruction, hematuria, dyspnea, acute kidney injury, abdominal pain, venous thromboembolism, sepsis, and pneumonia.[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (22%)

Common (1% to 10%): Urinary obstruction[Ref]

Hematologic

Common (1% to 10%): Anemia, lymphopenia, increased alkaline phosphatase, increased alkaline phosphatase[Ref]

Hepatic

Common (1% to 10%): Acute kidney injury, liver enzyme increase, increased ALT, increased AST

Immunologic

Very common (10% or more): Immune related colitis (19.7%)

Common (1% to 10%): Immune related pneumonitis, immune related hepatitis, sepsis

Frequency not reported: Immune related endocrinopathies[Ref]

Local

Frequency not reported: Infusion related reactions[Ref]

Metabolic

Very common (10% or more): Decreased appetite (26%)

Common (1% to 10%): Hyponatremia, hyperglycemia, hypoalbuminemia[Ref]

Musculoskeletal

Very common (10% or more): Back/neck pain (15%), arthralgia (14%)[Ref]

Nervous system

Frequency not reported: Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barre[Ref]

Ocular

Frequency not reported: Ocular inflammatory toxicity[Ref]

Other

Very common (10% or more): Fatigue (52%), pyrexia (21%), peripheral edema (18%)

Common (1% to 10%): Increased creatinine[Ref]

Psychiatric

Common (1% to 10%): Confusional state[Ref]

Renal

Common (1% to 10%): Hematuria[Ref]

Respiratory

Very common (10% or more): Dyspnea (16%), cough (14%)

Common (1% to 10%): Dyspnea, pneumonia[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Tecentriq (atezolizumab). Genentech. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer